Advertisement

Surgery for Testicular Cancer: UK and European Experience

  • David Kirk
Conference paper

Abstract

Surgery for metastatic testis cancer is done for several reasons. It gives diagnostic information, especially in staging apparent stage 1 disease, it provides prognostic information by defining the pathological results of chemotherapy, and, most importantly, is done therapeutically, to remove residual viable disease. The purpose of this article is to define European practice, for comparison with that in the USA, as described elsewhere by Foster and colleagues. The author will, of necessity, provide the most detailed information on UK, rather than general European, practice, using data, involving 909 patients (Table 34.1), from a survey carried out of the majority of British centres performing surgery for metastatic testis cancer [1].

Keywords

Germ Cell Tumour Testicular Cancer European Experience Nerve Spare Interventional Surgery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Kirk D, Fordham MVP, Wallace DM et al. Surgery for metastatic germ cell tumours: a survey of practice in Britain. UroOncology 2001;1:123–129Google Scholar
  2. 2.
    Ravi R, Ong J, Oliver RTD, Badenoch DF, Fowler CG, Hendry WF. The management of residual masses after chemotherapy in metastatic seminoma. BJU Int 1999;83:649–53.PubMedCrossRefGoogle Scholar
  3. 3.
    Wood DP, Herr HW, Heller G et al. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol 1992;148:1812–5PubMedGoogle Scholar
  4. 4.
    Donohue JP. Editorial comment on “Distribution of peritoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumours.” J Urol 1992;148;1815–1817Google Scholar
  5. 5.
    Fossa S, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky KE. Is post-chemotherapy retroperintoneal surgery necessary in patients with non-seminomatous testicular cancer and minimal residual tumour masses. J Clin Oncol 1990;10;569–573Google Scholar
  6. 6.
    Steyerberg E, Keizer H, Fossa S et al. Prediction of residual retroperitoneal mass histology after chemotherapy for metastatic nonseminomatous germ cell tumour: multivariate analysis of individual patient data from six study groups. J Clin Oncol 1995; 13:1177–1187PubMedGoogle Scholar
  7. 7.
    Steyerberg EW, Keizer JH, Messemer JE et al. Residual pulmonary masses after chemotherapy for metastatic nonseminomatous germ cell tumour. Cancer 1997;79:345–355.PubMedCrossRefGoogle Scholar
  8. 8.
    Hollins GW, Thomas S, Lanigan DJ et al. Retroperitoneal surgery: its wider role in the management of malignant teratoma. Br J Urol 1996;77:571–576PubMedCrossRefGoogle Scholar
  9. 9.
    Eastham JA, Wilson TG, Russell C, Ahlering TE, Skinner DG. Surgical resection in patients with nonseminomatous germ cell tumour who fail to normalize serum tumour markers after chemotherapy. Urology 1994;43:74–80PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2002

Authors and Affiliations

  • David Kirk
    • 1
  1. 1.Urology DepartmentGartnavel General HospitalGlasgowUK

Personalised recommendations